Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altropane pivotal trial agreement

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Boston Life Sciences will proceed with a single pivotal trial for its Parkinson's disease radioimaging agent Altropane under a special protocol assessment. Agreement was reached after "a number of teleconferences, meetings and protocol revisions occurring over an eight-month period in which the company and FDA refined the study design," BLS says. The study will enroll at least 500 patients (250 with PD tremor, 250 with non-PD tremor). Primary analyses will evaluate Altropane's sensitivity and specificity versus that of an internist/general practitioner in distinguishing PD tremors from non-PD tremors. The agent is also in Phase II studies for diagnosis of attention deficit/hyperactivity disorder...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel